Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM)

Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

NCT04992949 ·Status: COMPLETED ·Phase: PHASE2

Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders

NCT02823210 ·Status: UNKNOWN

Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)

NCT06649006 ·Status: COMPLETED ·Phase: PHASE1

Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic Leukemia

NCT00917540 ·Status: UNKNOWN

Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)

NCT01195506 ·Status: UNKNOWN

Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study

NCT06649422 ·Status: NOT_YET_RECRUITING

Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children

NCT00287105 ·Status: COMPLETED ·Phase: PHASE2

Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects

NCT06536452 ·Status: RECRUITING

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

NCT04827719 ·Status: COMPLETED ·Phase: PHASE2

Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)

NCT04048564 ·Status: COMPLETED

Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms

NCT01650467 ·Status: WITHDRAWN

A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms

NCT04272957 ·Status: UNKNOWN ·Phase: PHASE1

DHPLC Determination of TPMT Polymorphisms.

NCT00402090 ·Status: UNKNOWN

Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

NCT05246345 ·Status: RECRUITING

A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)

NCT05673460 ·Status: COMPLETED ·Phase: PHASE1

Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

NCT00906945 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Chemotherapy-related Cognitive Impairment and Acute Leukemia

NCT04644419 ·Status: COMPLETED

Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

NCT03824080 ·Status: COMPLETED ·Phase: PHASE2

COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias

NCT04416438 ·Status: COMPLETED

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

NCT00943943 ·Status: COMPLETED ·Phase: PHASE1

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib

NCT01343173 ·Status: COMPLETED ·Phase: NA

Prognostic Role of Platelet _lymphocyte and Neutrophil _monocyte in CLL

NCT04811950 ·Status: UNKNOWN

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

NCT06253663 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm

NCT04312607 ·Status: UNKNOWN

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia

NCT05944211 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2